Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

PURPOSE: Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report 3-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or docetaxel) in patients with previously treated ESCC. PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Morihito, Kato, Ken, Cho, Byoung Chul, Takahashi, Masanobu, Lin, Chen-Yuan, Chin, Keisho, Kadowaki, Shigenori, Ahn, Myung-Ju, Hamamoto, Yasuo, Doki, Yuichiro, Yen, Chueh-Chuan, Kubota, Yutaro, Kim, Sung-Bae, Hsu, Chih-Hung, Holtved, Eva, Xynos, Ioannis, Matsumura, Yasuhiro, Takazawa, Akira, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662935/
https://www.ncbi.nlm.nih.gov/pubmed/35294546
http://dx.doi.org/10.1158/1078-0432.CCR-21-0985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662935/
https://www.ncbi.nlm.nih.gov/pubmed/35294546
http://dx.doi.org/10.1158/1078-0432.CCR-21-0985

Ejemplares similares